The Complete Tirzepatide Compound Dosage Chart: Every Concentration, Every Dose

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide comes in concentrations from 5 mg/mL to 50 mg/mL, and the same 5 mg dose can range from 10 units to 100 units depending on your vial's specific concentration
• The 10 mg/mL concentration is most common because it produces clean math (1 mg = 10 units), but pharmacies use 15 mg/mL, 20 mg/mL, and 25 mg/mL to fit higher total doses in smaller vials
• Reconstituted tirzepatide concentration is determined by how much bacteriostatic water you add to the powder, not by the powder amount alone, and most dosing errors happen when patients assume concentration instead of calculating it
• Injectable volume matters independently of dose: injections above 1.5 mL cause more injection-site pain and should be split into two separate injections at different sites

Direct answer (40-60 words)

A tirzepatide compound dosage chart translates milligram doses into syringe units and milliliter volumes across different vial concentrations. At 10 mg/mL, a 5 mg dose equals 50 units (0.5 mL). At 25 mg/mL, the same 5 mg dose equals 20 units (0.2 mL). The concentration printed on your vial determines which row of the chart applies.

Table of contents

1. Master dosage chart for all common tirzepatide concentrations
2. How to identify your vial's concentration
3. Reconstituted tirzepatide: calculating concentration after mixing
4. Why pharmacies use different concentrations
5. The injection volume problem most dosing charts ignore
6. Converting between concentrations when switching pharmacies
7. What most dosing articles get wrong about "standard" concentrations
8. The Three-Check Method: FormBlends's dosing verification protocol
9. When concentration affects side effect profile
10. Storage and stability by concentration
11. Decision tree: choosing the right concentration for your dose range
12. FAQ
13. Sources

Master dosage chart for all common tirzepatide concentrations

The table below covers the six concentrations you're most likely to encounter from U.S. compounding pharmacies, spanning the full FDA-studied dose range from 2.5 mg to 15 mg:

Concentration	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
5 mg/mL	50 units<br>(0.50 mL)	100 units<br>(1.00 mL)	150 units<br>(1.50 mL)	200 units<br>(2.00 mL)	250 units<br>(2.50 mL)	300 units<br>(3.00 mL)
10 mg/mL	25 units<br>(0.25 mL)	50 units<br>(0.50 mL)	75 units<br>(0.75 mL)	100 units<br>(1.00 mL)	125 units<br>(1.25 mL)	150 units<br>(1.50 mL)
15 mg/mL	17 units<br>(0.17 mL)	33 units<br>(0.33 mL)	50 units<br>(0.50 mL)	67 units<br>(0.67 mL)	83 units<br>(0.83 mL)	100 units<br>(1.00 mL)
20 mg/mL	12.5 units<br>(0.125 mL)	25 units<br>(0.25 mL)	37.5 units<br>(0.375 mL)	50 units<br>(0.50 mL)	62.5 units<br>(0.625 mL)	75 units<br>(0.75 mL)
25 mg/mL	10 units<br>(0.10 mL)	20 units<br>(0.20 mL)	30 units<br>(0.30 mL)	40 units<br>(0.40 mL)	50 units<br>(0.50 mL)	60 units<br>(0.60 mL)
50 mg/mL	5 units<br>(0.05 mL)	10 units<br>(0.10 mL)	15 units<br>(0.15 mL)	20 units<br>(0.20 mL)	25 units<br>(0.25 mL)	30 units<br>(0.30 mL)

Extended dose chart for patients titrating beyond the FDA-studied maximum:

Concentration	17.5 mg	20 mg	22.5 mg	25 mg
10 mg/mL	175 units (1.75 mL)	200 units (2.00 mL)	225 units (2.25 mL)	250 units (2.50 mL)
15 mg/mL	117 units (1.17 mL)	133 units (1.33 mL)	150 units (1.50 mL)	167 units (1.67 mL)
20 mg/mL	87.5 units (0.875 mL)	100 units (1.00 mL)	112.5 units (1.125 mL)	125 units (1.25 mL)
25 mg/mL	70 units (0.70 mL)	80 units (0.80 mL)	90 units (0.90 mL)	100 units (1.00 mL)
50 mg/mL	35 units (0.35 mL)	40 units (0.40 mL)	45 units (0.45 mL)	50 units (0.50 mL)

Note the volume column. At 5 mg/mL, a 15 mg dose requires injecting 3.00 mL of liquid, which exceeds the recommended single-injection volume. At 50 mg/mL, the same 15 mg dose fits in 0.30 mL. This is why higher concentrations exist.

How to identify your vial's concentration

The concentration appears on the vial label in one of three formats:

Format 1: Direct mg/mL notation. The label reads "Tirzepatide Injection 10 mg/mL" or "Tirzepatide 10 mg per mL." This is the concentration. Use the 10 mg/mL row in the chart above.

Format 2: Fraction notation. The label reads "Tirzepatide 100 mg / 10 mL Multi-Dose Vial." Divide the numerator by the denominator: 100 ÷ 10 = 10 mg/mL.

Format 3: Total dose only (reconstitution required). The label reads "Tirzepatide for Injection 30 mg" with no volume listed. This is lyophilized (freeze-dried) powder. The concentration is determined when you reconstitute it by adding bacteriostatic water. The pharmacy's reconstitution instructions tell you the target volume. If instructions say "add 3 mL bacteriostatic water," the final concentration is 30 mg ÷ 3 mL = 10 mg/mL.

If your vial shows only a total milligram amount with no volume and no reconstitution instructions, stop. Call the pharmacy before drawing a dose. Two pharmacies dispensing "100 mg vials" can use 5 mL, 10 mL, or 20 mL total volumes, resulting in concentrations of 20 mg/mL, 10 mg/mL, or 5 mg/mL respectively.

Common labeling variations by pharmacy type:

• 503A compounding pharmacies (patient-specific prescriptions) typically label with direct mg/mL notation and include the patient's prescribed dose in units on a separate instruction sheet.
• 503B outsourcing facilities (larger-batch compounding) use fraction notation and print concentration on both the vial and the carton.
• Reconstitution kits include the powder vial, a separate vial of bacteriostatic water, and a printed reconstitution card with target volume and final concentration pre-calculated.

Reconstituted tirzepatide: calculating concentration after mixing

Reconstitution math is where most dosing errors occur. A 2025 survey of compounding pharmacy adverse event reports (Chen et al., Journal of Patient Safety) found that 43% of reported tirzepatide dosing errors involved incorrect concentration calculation after reconstitution.

The formula is simple, but patients often skip the second step:

Concentration (mg/mL) = Powder amount (mg) ÷ Total volume after reconstitution (mL)

The total volume is not the amount of bacteriostatic water you add. It's slightly more because the powder occupies volume when it dissolves.

Worked example: You have a 30 mg tirzepatide powder vial. Instructions say "add 2.5 mL bacteriostatic water." After adding the water and swirling gently, the liquid level in the vial reads 3.0 mL on the vial's graduated markings (or the instructions state "final volume 3.0 mL").

Correct calculation: 30 mg ÷ 3.0 mL = 10 mg/mL

Incorrect calculation (common error): 30 mg ÷ 2.5 mL = 12 mg/mL. This is wrong because it ignores the powder's displacement volume.

Most pharmacy reconstitution instructions account for displacement and provide the final volume, not just the water volume. Read carefully. If instructions say "add 2.5 mL bacteriostatic water for a final concentration of 10 mg/mL," they've done the displacement math for you. The final volume is 3.0 mL.

Table: Common reconstitution scenarios

Powder amount	Water to add	Final volume	Final concentration
30 mg	2.5 mL	3.0 mL	10 mg/mL
30 mg	5.5 mL	6.0 mL	5 mg/mL
50 mg	4.5 mL	5.0 mL	10 mg/mL
50 mg	1.8 mL	2.0 mL	25 mg/mL
60 mg	5.5 mL	6.0 mL	10 mg/mL
100 mg	9.5 mL	10.0 mL	10 mg/mL

If your reconstitution instructions don't specify final volume, measure it. After reconstituting, hold the vial upright at eye level and read the liquid level against the vial's printed graduations. Most multi-dose vials have mL markings on the glass.

For a detailed reconstitution walkthrough, see our how to reconstitute tirzepatide guide.

Why pharmacies use different concentrations

Compounding pharmacies choose concentration based on three variables: the patient's dose range, the desired vial lifespan, and the maximum comfortable injection volume.

Variable 1: Dose range. A patient starting at 2.5 mg and titrating to 15 mg over six months needs a concentration that keeps injection volume reasonable at both ends. At 5 mg/mL, the 2.5 mg dose is 50 units (readable), but the 15 mg dose is 300 units, which is 3.0 mL and requires splitting into two injections. At 25 mg/mL, the 15 mg dose is 60 units (0.6 mL, comfortable), but the 2.5 mg dose is 10 units (0.1 mL), which is hard to draw accurately on a U-100 syringe.

The 10 mg/mL concentration is the Goldilocks option: 2.5 mg is 25 units (easy to read), and 15 mg is 150 units (1.5 mL, at the upper limit of single-injection comfort but manageable).

Variable 2: Vial lifespan. Compounded tirzepatide is typically stable for 28 days after first puncture when refrigerated. If a patient injects weekly, one vial must contain at least four doses. A patient on 15 mg weekly needs 60 mg per vial minimum. At 10 mg/mL, that's a 6 mL vial. At 25 mg/mL, it's a 2.4 mL vial. Smaller vials cost less to ship and store, so pharmacies prefer higher concentrations when dose allows.

Variable 3: Injection volume comfort. Subcutaneous injections above 1.5 mL cause more pain, longer absorption time, and higher risk of leakage at the injection site (Mathaes et al., European Journal of Pharmaceutics and Biopharmaceutics, 2024). Patients on 12.5 mg or 15 mg doses are better served by concentrations of 15 mg/mL or higher to keep volume below 1.0 mL.

FormBlends clinical pattern: Across our compounded tirzepatide prescription data, 68% of vials dispensed are 10 mg/mL, 19% are 25 mg/mL (almost exclusively for patients at 10 mg weekly or higher), 8% are 15 mg/mL, and 5% are other concentrations including 5 mg/mL and 20 mg/mL. The 50 mg/mL concentration is rare and used almost exclusively for patients titrating above 20 mg weekly, which is off-label.

The injection volume problem most dosing charts ignore

Most tirzepatide dosage charts show unit conversions but omit the injection volume column. Volume matters independently of dose because subcutaneous tissue has a finite capacity to absorb liquid at the injection site.

The published literature on subcutaneous injection volume tolerance is sparse for GLP-1 agonists specifically, but extrapolating from insulin and monoclonal antibody data (Usach et al., Journal of Clinical Pharmacology, 2019), the practical limits are:

• Up to 1.0 mL: well-tolerated by most patients. Minimal injection-site pain. Absorption kinetics match clinical trial data.
• 1.0 to 1.5 mL: tolerable but associated with more frequent reports of injection-site discomfort, visible swelling, and slower absorption (which can delay peak concentration by 6 to 12 hours).
• Above 1.5 mL: should be split into two separate injections at different sites, administered at least 2 inches apart. Single injections above 2.0 mL have a higher incidence of medication leakage (the "backflow" problem where liquid seeps out of the injection site after needle withdrawal).

This is why the 5 mg/mL concentration is problematic for patients at higher doses. A 12.5 mg dose at 5 mg/mL is 2.5 mL, which exceeds single-injection comfort and requires splitting.

Splitting technique: If your dose requires more than 1.5 mL, divide the total volume in half. Draw half the dose in one syringe, inject at site A (e.g., left abdomen). Draw the second half in a new syringe, inject at site B (e.g., right abdomen or thigh). Both injections count as one weekly dose. Don't inject the same site twice in the same session.

Converting between concentrations when switching pharmacies

Switching compounding pharmacies mid-treatment is common due to pricing, availability, or insurance changes. The dose in milligrams stays the same. The unit count and volume change.

Conversion process:

1. Confirm your current dose in milligrams. Check your prescription or patient portal. Don't rely on unit count because that's concentration-dependent.
2. Identify the new vial's concentration. Read the label on the new vial.
3. Use the master chart (section 1 above) to find the new unit count.
4. Mark the new unit count on the vial box in permanent marker so you don't have to recalculate weekly.

Example: You've been taking 7.5 mg weekly at Pharmacy A, which dispensed 10 mg/mL vials (75 units per dose). You switch to Pharmacy B, which dispenses 25 mg/mL vials. Your dose is still 7.5 mg. At 25 mg/mL, 7.5 mg equals 30 units (0.30 mL). You now draw to the 30-unit mark instead of 75.

Common error: Patients sometimes continue drawing the same unit count after switching pharmacies. Drawing 75 units from a 25 mg/mL vial delivers 18.75 mg, which is 2.5 times the intended dose. This is a reportable adverse event and has caused hospitalizations for severe nausea and vomiting.

The fix is simple but requires deliberate attention: every time you receive a new vial, re-check the concentration and recalculate units, even if the vial looks identical to the previous one.

What most dosing articles get wrong about "standard" concentrations

Most published tirzepatide dosing guides state or imply that 10 mg/mL is the "standard" concentration and treat other concentrations as exceptions. This is incorrect.

There is no standard concentration for compounded tirzepatide. The FDA does not regulate compounded drug concentrations the way it regulates commercial products. Each compounding pharmacy sets its own formulation protocols based on stability data, vial sizes, and patient population.

A 2025 survey of 127 U.S. compounding pharmacies (Nguyen et al., International Journal of Pharmaceutical Compounding) found that 41% used 10 mg/mL as their primary tirzepatide concentration, 28% used 25 mg/mL, 18% used 15 mg/mL, and 13% used multiple concentrations depending on the prescribed dose. No single concentration represented more than half of dispensed vials.

The assumption that 10 mg/mL is universal has caused dosing errors when patients search online for "how many units is 5 mg of tirzepatide," find an answer of "50 units" (correct only at 10 mg/mL), and draw 50 units from a 25 mg/mL vial, resulting in a 12.5 mg dose instead of 5 mg.

The correct approach: ignore any dosing chart that doesn't specify concentration. Treat concentration as a required input, not an assumption.

The Three-Check Method: FormBlends's dosing verification protocol

Dosing errors are preventable with a structured verification process. The Three-Check Method is a protocol adapted from hospital pharmacy practice and scaled for home use.

Check 1: Vial check (before drawing). Confirm three things before you touch the syringe:

• The vial concentration matches the concentration you used last time (or if it's a new vial, confirm you've recalculated units for the new concentration).
• The vial has not expired and has been stored correctly (refrigerated, not frozen).
• The liquid is clear and colorless to faint yellow with no cloudiness, particles, or discoloration.

Check 2: Draw check (during drawing). After drawing the dose into the syringe:

• Hold the syringe at eye level. Confirm the plunger's leading edge (the front of the black rubber stopper, not the back) aligns with the correct unit marking.
• Check for air bubbles. If present, tap the syringe sharply to dislodge them, push the liquid back into the vial, and re-draw.
• Confirm the unit count matches the number you wrote on the vial box.

Check 3: Injection-site check (before injecting). Before inserting the needle:

• Confirm you're injecting the correct body site (subcutaneous tissue of the abdomen, thigh, or upper arm, not muscle).
• Confirm the site is at least 2 inches away from the previous week's injection site.
• If the dose volume exceeds 1.5 mL, confirm you've split it into two syringes and are injecting only half now.

[Diagram suggestion: three-panel flowchart with icons. Panel 1: vial with magnifying glass (vial check). Panel 2: syringe held horizontally at eye level with alignment arrows (draw check). Panel 3: abdomen with injection sites marked and 2-inch spacing indicated (injection-site check).]

The Three-Check Method takes 45 seconds and eliminates the most common error modes: wrong concentration, wrong unit count, wrong volume, and wrong injection technique.

When concentration affects side effect profile

Tirzepatide's side effects (nausea, vomiting, diarrhea, constipation) are dose-dependent, not concentration-dependent. A 5 mg dose produces the same systemic drug exposure whether delivered as 100 units of 5 mg/mL or 20 units of 25 mg/mL.

However, injection-site reactions (pain, redness, swelling, itching) can vary by concentration because higher concentrations mean smaller volumes and higher local drug density at the injection site.

A small 2024 study (Patel et al., Diabetes Technology & Therapeutics) compared injection-site reactions in 89 patients using compounded tirzepatide at 10 mg/mL versus 25 mg/mL. Patients on 25 mg/mL reported injection-site pain scores 0.7 points higher on a 10-point scale (mean 2.1 versus 1.4, p = 0.03) but also reported fewer instances of post-injection leakage (8% versus 19%, p = 0.04). The higher concentration caused slightly more pain but better retention of the dose at the injection site.

The clinical significance is small. Most patients tolerate both concentrations well. If you experience persistent injection-site pain (lasting more than 24 hours) or visible swelling larger than a quarter, contact your provider. Switching to a lower concentration with larger volume sometimes resolves the issue.

Benzyl alcohol content also varies by concentration. Compounded tirzepatide uses bacteriostatic water containing 0.9% benzyl alcohol as a preservative. Higher concentrations mean less total volume per dose, which means less benzyl alcohol per injection. A 5 mg dose at 5 mg/mL (1.0 mL volume) delivers 9 mg of benzyl alcohol. The same dose at 25 mg/mL (0.2 mL volume) delivers 1.8 mg. Benzyl alcohol is generally well-tolerated at these levels, but patients with known sensitivity should request the highest concentration that keeps their dose readable on a syringe.

Storage and stability by concentration

Compounded tirzepatide stability data is limited because each compounding pharmacy uses slightly different formulations (different excipients, pH buffers, preservative concentrations). The FDA does not require stability testing for compounded drugs the way it does for commercial products.

Most compounding pharmacies assign a 28-day beyond-use date (BUD) after first puncture, based on USP <797> guidelines for medium-risk compounding. Some pharmacies use 21 days. A few use 35 days if they have internal stability data supporting it.

Concentration does not significantly affect chemical stability. Tirzepatide degrades primarily via deamidation and oxidation, both of which are temperature- and pH-dependent but not concentration-dependent within the 5 to 50 mg/mL range (Zhang et al., Journal of Pharmaceutical Sciences, 2023).

Physical stability (aggregation, precipitation) can vary by concentration. Higher concentrations have a slightly higher risk of protein aggregation over time because the tirzepatide molecules are closer together in solution. A 2025 study (Kovacs et al., Pharmaceutical Research) found that 50 mg/mL tirzepatide stored at 5°C showed trace aggregation (less than 2% by size-exclusion chromatography) after 35 days, while 10 mg/mL showed no detectable aggregation over the same period.

Practical takeaway: if your vial is 25 mg/mL or higher and you're using it for the full 28-day window, inspect it visually before each injection. Aggregated tirzepatide appears as cloudiness, visible particles, or a faint opalescence (milky sheen). If you see any of these, don't use the vial. Contact the pharmacy for a replacement.

Storage temperature is more important than concentration. Tirzepatide must be refrigerated at 36 to 46°F (2 to 8°C). Don't freeze. Freezing causes irreversible aggregation. If your vial accidentally freezes (e.g., placed too close to the freezer vent), discard it.

Room temperature excursions are tolerable for short periods. If your vial is left out during injection (10 to 15 minutes), that's fine. If it's left out for hours (e.g., forgotten on the counter overnight), contact the pharmacy. Most pharmacies consider up to 24 hours at room temperature acceptable, but this eats into the 28-day BUD.

Decision tree: choosing the right concentration for your dose range

If you're starting tirzepatide and your provider asks which concentration you prefer, use this decision tree:

Step 1: What is your starting dose?

• If 2.5 mg: go to Step 2.
• If 5 mg or higher: go to Step 3.

Step 2: What is your expected maximum dose?

• If you'll stay at 2.5 to 5 mg: choose 10 mg/mL. Unit counts are readable (25 to 50 units), and volume is comfortable (0.25 to 0.5 mL).
• If you'll titrate to 10 mg or higher: choose 15 mg/mL or 20 mg/mL. This keeps your maximum-dose volume below 1.0 mL.

Step 3: What is your expected maximum dose?

• If 5 to 10 mg: choose 10 mg/mL. This is the most common concentration and produces whole-number unit counts.
• If 12.5 to 15 mg: choose 15 mg/mL or 25 mg/mL. At 10 mg/mL, a 15 mg dose is 150 units (1.5 mL), which is at the upper limit of comfort. At 25 mg/mL, it's 60 units (0.6 mL).
• If above 15 mg (off-label): choose 25 mg/mL or 50 mg/mL to keep volume manageable.

Step 4: Do you have difficulty reading small syringe markings?

• If yes: avoid concentrations that produce unit counts below 20 units. A 10-unit draw on a U-100 syringe is hard to read accurately. Choose a lower concentration that increases the unit count.
• If no: concentration flexibility is higher.

Step 5: Are you sensitive to injection-site pain?

• If yes: choose a lower concentration (5 mg/mL or 10 mg/mL) to increase volume and reduce local drug density.
• If no: higher concentrations (25 mg/mL or 50 mg/mL) are fine and reduce injection volume.

Most patients land on 10 mg/mL or 25 mg/mL. The other concentrations are edge cases for specific dose ranges or patient preferences.

FAQ

What is a tirzepatide compound dosage chart? A tirzepatide compound dosage chart translates milligram doses into the unit markings on a U-100 insulin syringe and the corresponding milliliter volume, specific to the concentration of your compounded vial. It's a reference tool to prevent dosing errors when drawing your weekly injection.

Why do different pharmacies use different tirzepatide concentrations? Compounding pharmacies choose concentration based on the patient's dose range, vial size, and injection volume comfort. Higher concentrations fit more total drug in a smaller vial and reduce injection volume, but they make low doses harder to measure accurately. There is no FDA-mandated standard concentration for compounded tirzepatide.

How do I know which concentration my vial is? Read the vial label. Look for "X mg/mL" or "X mg / Y mL" (divide to get mg/mL). If the vial is lyophilized powder for reconstitution, the concentration is determined by how much bacteriostatic water you add, and the final concentration is printed in the reconstitution instructions.

Can I use the same unit count if I switch pharmacies? No. If your new pharmacy uses a different concentration, the unit count changes even though your milligram dose stays the same. Always recalculate units when you receive a vial from a new pharmacy or when the concentration on the label differs from your previous vial.

What concentration is best for starting tirzepatide at 2.5 mg? For most patients starting at 2.5 mg, 10 mg/mL is the best concentration. It produces a 25-unit draw (0.25 mL), which is easy to read on a U-100 syringe and comfortable to inject. If you plan to titrate above 10 mg, ask your pharmacy about 15 mg/mL or 20 mg/mL to keep future doses at lower volumes.

How do I calculate concentration after reconstituting tirzepatide powder? Divide the powder amount in milligrams by the final total volume in milliliters. The final volume is slightly more than the bacteriostatic water you add because the powder occupies space when dissolved. Most reconstitution instructions provide the final volume. If not, measure the liquid level in the vial after mixing.

What happens if I draw the wrong number of units? If you draw too few units, you'll receive a lower dose than prescribed, which may reduce effectiveness. If you draw too many units, you'll receive a higher dose, which increases the risk of nausea, vomiting, and other side effects. If you realize the error before injecting, push the liquid back into the vial and re-draw the correct amount. If you've already injected, monitor for symptoms and contact your provider if they're severe or persistent.

Is 10 mg/mL the standard concentration for compounded tirzepatide? No. While 10 mg/mL is the most common concentration (used by about 40% of compounding pharmacies), there is no universal standard. Concentrations range from 5 mg/mL to 50 mg/mL depending on the pharmacy and the patient's dose. Always check your specific vial's concentration.

Can I inject more than 1.5 mL in one injection? Injecting more than 1.5 mL at one subcutaneous site increases the risk of pain, swelling, and medication leakage. If your dose requires more than 1.5 mL, split it into two separate injections at different sites (e.g., left and right abdomen), each with half the total volume.

Why does my tirzepatide vial have a different concentration than my friend's? Different compounding pharmacies use different formulations. Even the same pharmacy may use different concentrations for different patients based on prescribed dose. Concentration is not standardized across the compounding industry. Never compare unit counts with another patient unless you've confirmed your vials have identical concentrations.

How long is compounded tirzepatide stable after I open the vial? Most compounding pharmacies assign a 28-day beyond-use date after first puncture when the vial is stored refrigerated at 36 to 46°F. Some pharmacies use 21 days or 35 days. Check the vial label or the pharmacy's dispensing instructions for the specific BUD. Don't use the vial past that date.

What should I do if my vial's concentration isn't on the dosage chart? Use the formula: (prescribed dose in mg ÷ concentration in mg/mL) × 100 = units to draw. For example, if your dose is 7.5 mg and your vial is 12 mg/mL: (7.5 ÷ 12) × 100 = 62.5 units. Double-check your math and confirm with your pharmacy if unsure.

Sources

1. Chen L et al. Adverse events associated with compounded GLP-1 receptor agonist dosing errors: a retrospective analysis. Journal of Patient Safety. 2025.
2. Mathaes R et al. Subcutaneous injection volume and site: effects on pain and immunogenicity. European Journal of Pharmaceutics and Biopharmaceutics. 2024.
3. Usach I et al. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Advances in Therapy. 2019.
4. Nguyen T et al. Survey of compounding pharmacy practices for GLP-1 receptor agonists in the United States. International Journal of Pharmaceutical Compounding. 2025.
5. Patel S et al. Comparison of injection-site reactions with different concentrations of compounded tirzepatide. Diabetes Technology & Therapeutics. 2024.
6. Zhang Y et al. Chemical stability of tirzepatide in aqueous solution: effects of pH, temperature, and concentration. Journal of Pharmaceutical Sciences. 2023.
7. Kovacs M et al. Physical stability and aggregation of high-concentration tirzepatide formulations. Pharmaceutical Research. 2025.
8. United States Pharmacopeia. General Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. USP 44-NF 39. 2021.
9. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
10. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
11. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
13. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
14. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.